Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis

Kidney International

Volumn 67, Issue 3, 2005, Pages 1136-1141

  Ahuja, Tejinder S ^a   Kumar, Sajal ^a   Mansoury, Hadi ^a   Rodriguez, Hector ^a   Kuo, Yong Fang ^a  

^a 4200 John Sealy Annex ^*

Author keywords

Chronic kidney disease; Hemodialysis; Hepatitis B; Human immunodeficiency virus; Vaccination

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT VACCINE; HEPATITIS B ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; ETHNOLOGY; FEMALE; HEMODIALYSIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; KIDNEY FAILURE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION; AGED; BLOOD; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; VACCINATION;

EID: 20844432544     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00180.x     Document Type: Article

References (42)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION: Hepatitis: Control Measures for Hepatitis B in Dialysis Centers, Atlanta, GA, US Department of Health, Education, and Welfare, Public Health Services, 1977
2. CENTERS FOR DISEASE CONTROL AND PREVENTION: Outbreaks of hepatitis B virus infection among hemodialysis patients-California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep 45:285-289, 1996
3. FAVERO MS, ALTER MJ: The reemergence of hepatitis B virus infection in hemodialysis centers. Semin Dial 9:373-374,1996
4. TOKARS JI, ALTER MJ, FAVERO MS, et al: National surveillance of dialysis associated diseases in the United States, 1993. ASAIO J 42: 219-229,1993
5. CENTERS FOR DISEASE CONTROL AND PREVENTION: Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep 50:2-9, 2001
6. RIBOT S, ROTHSTEIN M, GOLDBLAT M, GRASSO M: Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 139:178-180,1979
7. CDC. RECOMMENDATIONS OF THE IMMUNIZATION PRACTICE ADVISORY COMMITTEE (ACIP): inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 31:317-322, 327-328,1982
8. STEVENS CE, ALTER HJ, TAYLOR PE, et al: Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 311:496-501,1984
9. GROB P: Hepatitis B vaccination of renal transplant and hemodialysis patients. Scand J Infect Dis 38:28-32,1983
10. DE GRAEFF PA, DANKERT J, DE ZEEUW D, et al: Immune response to two different hepatitis vaccines in haemodialysis patients: A 2-year follow-up. Nephron 40:155-160,1985
11. NAVARRO JF, TERUEL JL, MATEOS ML, et al: Antibody level after hepatitis B vaccination in hemodialysis patients: Influence of hepatitis C virus infection. Am J Nephrol 16: 95-97,1996
12. BRUGUERA M, CREMADES M, MAYOR A, et al: Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J 63(Suppl 2):155-158,1987
13. BRUGUERA M, RODICIO JL, ALCAZAR JM, et al: Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 8(Suppl):S47-S49,1990
14. WAITE NM, THOMPSON LG, GOLDSTEIN MB: Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrot 5:1930-1934,1995
15. CHANG PC, SCHRANDER-VAN DER MEER AM, VAN DORP WT, VAN LEER E: Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 11:191-193,1996
16. KURZ P, KOHLER H, MEUER S, et al: Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect. Kidney Int 29:1209-1214,1986
17. DUMANN H, MEUER S, MEYER-ZUM-BUSCHENFELDE KH, KOHLER H: Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Kidney Int 38:1164-1168,1990
18. U.S. RENAL DATA SYSTEM: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
19. BODSWORTH NJ, COOPER DA, DONOVAN B: The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163:1138-1140,1991
20. WONG EK, BODSWORTH NJ, SLADE MA, et al: Response to hepatitis B vaccination in a primary care setting: Influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J of STD AIDS 7:490-94,1996
21. HORVATH J, RAFFANTS SP: Clinical aspects of the interaction between human immunodeficiency virus and the hepatatrophic viruses. Clin Infect Dis 18:339-347,1994
22. SOLOMON RE, VAN RADEN M, KASLEW KA, et al: Association of hepatitis B surface antigen and core antibody with acquisition and manifestation of human immunodeficiency virus type 1 (HIV-I) infection. Am J Public Health 80:1475-1478,1990
23. COLLIER AC, LAWRENCE C, MURPHY VL, HANDSFIELD H: Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 109:101-105,1988
24. LOKE R, MURRAY-LYON IM, COLEMAN JC, et al: Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody. J Med Virol 31:109-111,1990
25. CARNE CA, WELLER I, WAITE J, et al: Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. BMJ 294:866-868,1987
26. KEET IPM, VAN DOORNUM G, SAFARY A, COUTINHO RA: Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 6:509-522,1992
27. REY D, KRANTZ V, PARTISANI M, et al: Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-I viral load. Vaccine 18:1161-1165, 2000
28. CENTERS FOR DISEASE CONTROL AND PREVENTION: Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 42(RR-4):1-12, 1993
29. HUANG K-L, RUBEN FL, RINALDO CR, et al: Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 235:2047-2050,1987
30. LEROUX-ROELS GR, VAN HECKE E, MICHIELSEN W, et al: Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccine. Vaccine 12:812-818,1994
31. HADLER SC, MARGOLIS HS: Hepatitis B immunization: Vaccine types, efficacy, and indications for immunization, in Current Clinical Topics in Infectious Diseases, edited by Remington JS, Swartz MN, Boston, MA, Blackwell Scientific Publications, 1992, pp 282-308
32. AVERHOFF F, MAHONEY F, COLEMAN P, et al: Immunogenicity of hepatitis B vaccines: Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 15:1-8,1998
33. PECES R, DE LA TORRE M, ALCAZAR R, URRA JM: Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 29:239-245, 1997
34. BRIGGAR RJ, GOEDERT J, HOOFNAGLE J: Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 316:630-631,1987
35. MENICALGI V, BARBANERA M, MENICAGLI S: The immunogenicity of hepatitis B vaccine in drug addicts with human immunodeficiency virus infection. Recenti Prog Med 82: 69-71,1991
36. HASSAN K, SNTERNBERG L, ALHAJ M, et al: The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease. Ren Fail 25:47-48, 2003
37. ANANDH U, THOMAS PP, SHASTRY JC, JACOB CK: A randomized controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. J Assoc Phy Ind 48:1061-1063, 2000
38. SENNESAEL JJ, VAN DER NIEPEN P, VERBEELEN DL: Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40:121-128, 1991
39. PERINBASKER S, BROD-MILLER C, PAL S, MATTANA J: Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol 16:280-286,1996
40. AHUJA TS, COLLINGE N, GRADY J, KHAN S: Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy? Am J Kidney Dis 41:1060-1064, 2003
41. KAUSZ A, PAHARI D: The value of vaccination in chronic kidney disease. Semin Dial 17:9-11, 2004
42. TOKAR JI, FINELLI L, ALTER MJ, ARDUINO MJ: National surveillance of dialysis-associated diseases in the United states, 2001. Semin Dial 17:310-319, 2004